Kolexia
Raffoux Emmanuel Hématologie
Raffoux Emmanuel
Hématologie
Hôpital Saint-Louis
Paris, France
457 Activités
50 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Leucémie-lymphome lymphoblastique à précurseurs B et T Syndromes myélodysplasiques Leucémie aiguë promyélocytaire Maladie résiduelle Aspergillose Lymphomes

Collaborateurs

Voir plus
Dombret Herve
Dombret Herve
Hôpital Saint-Louis, Paris, France
Ades Lionel
Ades Lionel
Hôpital Saint-Louis, Paris, France
Thomas Xavier
Thomas Xavier
Hôpital Lyon Sud, Pierre-Bénite, France
Fenaux Pierre
Fenaux Pierre
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Edimark
26 collaboration(s)
Dernière en 2023
Astellas
13 collaboration(s)
Dernière en 2023
Servier
10 collaboration(s)
Dernière en 2023
Celgene
8 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
Blood   07 mars 2024
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions.
Current hematologic malignancy reports   23 février 2024
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Essai Clinique (Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH)   22 février 2024
Germline CHEK2 mutations in patients with myeloid neoplasms.
Leukemia   20 février 2024
OGILAR: Open-label, Phase 2 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Essai Clinique (French Innovative Leukemia Organisation)   05 février 2024
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.
American journal of hematology   26 janvier 2024
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Annals of hematology   26 janvier 2024
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy: A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Essai Clinique (Celgene)   23 janvier 2024
Leucémie aiguë
Edimark   16 janvier 2024
Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia.
Critical care (London, England)   05 janvier 2024